Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Solid Tumor 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1

Interventions

fludarabine 8Cyclophosphamide 7Specimen Handling 6Cytarabine 6fludarabine phosphate 5Methotrexate 5venetoclax 4merphos 4Whole-Body Irradiation 4calaspargase pegol 3Tacrolimus 3Spinal Puncture 3Mycophenolic Acid 3Melphalan 3Granulocyte Colony-Stimulating Factor 3Busulfan 3Biopsy 3Asparaginase 3vedolizumab 2prednylidene 2pegaspargase 2deltacortene 2decitabine and cedazuridine drug combination 2blinatumomab 2Vincristine 2Thiotepa 2Stem Cell Transplantation 2Rituximab 2Prednisone 2Prednisolone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Biphenotypic, Acute × cedazuridine × Clear all
NCT04980404 2026-03-30

Inqovi Maintenance Therapy in Myeloid Neoplasms

Massachusetts General Hospital

Phase 1 Active not recruiting
22 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡